Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial

Siebert, S, Pratt, AG, Stocken, DD orcid.org/0000-0001-8031-1738 et al. (9 more authors) (2020) Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial. Medicine, 99 (26). e20458. ISSN 0025-7974

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Keywords: Bayesian Continual Reassessment Method; cyclin-dependent kinase; dose-finding; fibroblast; Fleming A'Hern design; rheumatoid arthritis; seliciclib
Dates:
  • Accepted: 28 April 2020
  • Published (online): 26 June 2020
  • Published: 26 June 2020
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 20 Aug 2020 14:07
Last Modified: 20 Aug 2020 14:07
Status: Published
Publisher: Wolters Kluwer Health
Identification Number: https://doi.org/10.1097/md.0000000000020458
Related URLs:

Export

Statistics